中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2014年
5期
25-26
,共2页
阿奇霉素%序贯疗法%小儿支原体肺炎%临床疗效
阿奇黴素%序貫療法%小兒支原體肺炎%臨床療效
아기매소%서관요법%소인지원체폐염%림상료효
Azithromycin%Sequential therapy%Mycoplasma pneumonia%Clinical efficacy
目的：探讨阿奇霉素序贯疗法对小儿支原体肺炎的治疗效果。方法将98例小儿支原体肺炎患者按照入院时间先后顺序随机分为两组，每组49例，分别标记为对照组、实验组。对照组患者给予阿奇霉素静脉连续滴注，实验组患者采用阿奇霉素静脉注射，连续5 d后转为阿奇霉素口服治疗，比较两组患者治疗效果。结果实验组患者治疗有效率为91.83%，对照组治疗有效率为59.18%，两组比较差异具有统计学意义(P<0.05)。实验组患者8例患者发生不良反应，发生率为16.32%，对照组患者24例患者发生不良反应，发生率为48.97%，两组患者比较差异具有统计学意义(P<0.05)。结论阿奇霉素序贯疗法治疗小儿支原体肺炎临床疗效确切，不良反应较少，值得临床推广应用。
目的：探討阿奇黴素序貫療法對小兒支原體肺炎的治療效果。方法將98例小兒支原體肺炎患者按照入院時間先後順序隨機分為兩組，每組49例，分彆標記為對照組、實驗組。對照組患者給予阿奇黴素靜脈連續滴註，實驗組患者採用阿奇黴素靜脈註射，連續5 d後轉為阿奇黴素口服治療，比較兩組患者治療效果。結果實驗組患者治療有效率為91.83%，對照組治療有效率為59.18%，兩組比較差異具有統計學意義(P<0.05)。實驗組患者8例患者髮生不良反應，髮生率為16.32%，對照組患者24例患者髮生不良反應，髮生率為48.97%，兩組患者比較差異具有統計學意義(P<0.05)。結論阿奇黴素序貫療法治療小兒支原體肺炎臨床療效確切，不良反應較少，值得臨床推廣應用。
목적：탐토아기매소서관요법대소인지원체폐염적치료효과。방법장98례소인지원체폐염환자안조입원시간선후순서수궤분위량조，매조49례，분별표기위대조조、실험조。대조조환자급여아기매소정맥련속적주，실험조환자채용아기매소정맥주사，련속5 d후전위아기매소구복치료，비교량조환자치료효과。결과실험조환자치료유효솔위91.83%，대조조치료유효솔위59.18%，량조비교차이구유통계학의의(P<0.05)。실험조환자8례환자발생불량반응，발생솔위16.32%，대조조환자24례환자발생불량반응，발생솔위48.97%，량조환자비교차이구유통계학의의(P<0.05)。결론아기매소서관요법치료소인지원체폐염림상료효학절，불량반응교소，치득림상추엄응용。
Objective To investigate the effect of azithromycin sequential therapy in children with mycoplasma pneumonia. Methods The 98 cases of mycoplasma pneumonia patients admitted to hospital in chronological order according to randomized into two groups, 49 cases were labeled as the control group, the experimental group. In the control group were treated with azithromycin intravenous continuous infusion, the experimental group were treated with intravenous azithromycin, 5 days in a row into oral azithromycin treatment, treatment groups were compared. Results Effective treatment of patients in the experimental group was 91.83%, the control group was 59.18% effective, the difference was statistically significant (P<0.05). 8 patients in the experimental group patients had side effects, the rate was 16.32%, 24 patients in the control group of patients the occurrence of side reactions, the rate was 48.97%, comparing the two groups were statistically significant differences (P<0.05). Conclusion Azithromycin sequential therapy mycoplasma pneumoniae clinical efficacy, fewer side effects, worthy of clinical application.
